A cute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are common devastating clinical syndromes characterised by non-cardiogenic pulmonary oedema, life-threatening respiratory failure, the need for mechanical ventilation and multiple organ failure in patients admitted to intensive care units. ALI/ARDS affects all age groups and is commonly encountered by physicians who care for critically ill patients. 1 Mortality remains high at 30-40%. Mortality attributable to ALI/ARDS is comparable to HIV infection, breast cancer, and asthma. 2 There are probably more than 7,000 deaths per year in the UK in patients from ALI/ARDS. As well as a high mortality, ALI/ARDS causes a long-term reduction in quality of life for survivors. 3 Delivery of critical care to patients with ALI/ARDS accounts for a significant proportion of the capacity of intensive care units.
Currently, the only treatment proven to effectively decrease mortality for ALI/ARDS is a ventilatory strategy that limits tidal volume to 6 mL/kg predicted body weight and plateau pressure to less than 30 cm H 2 O. 4 Many pharmacologic treatments for ALI/ARDS have been evaluated, but none have clearly decreased mortality. A recent Cochrane systematic review of pharmacological treatments that included 22 studies of 14 different drugs concluded that effective pharmacotherapy for ALI and ARDS is extremely limited, with insufficient evidence to support any specific intervention. 5, 6 There is therefore an urgent need to develop novel therapies to treat ALI/ARDS.
Evidence in support of the use of salbutamol in ARDS
There is good evidence from in vivo and in vitro human and animal studies that β-2 agonists may have a range of important beneficial effects in ARDS patients. 7 A single centre, randomised, double blind, placebo-controlled phase 2 study (BALTI-1) found treatment with a continuous intravenous infusion of salbultamol for seven days in adult patients with ARDS improved surrogate clinical outcomes including lung water and respiratory compliance. 8 This result prompted two large multicentre phase 3 studies to be undertaken investigating the effects of β-2 agonists in ALI/ARDS. In the US, the ARDS Network designed a study of nebulised salbutamol (albuterol in the USA) versus placebo in ALI; the ALTA study (NCT00434993). Delivering drugs by aerosol is attractive in that it results in high lung but low blood concentrations and so may reduce the incidence of systemic side effects compared to parenteral treatment. In contrast in the UK, the BALTI-2 study was designed to investigate whether intravenous salbultamol was effective in patients with ARDS.
This study used the same study protocol that was successful in the BALTI study and was funded by the MRC. When completed, this will be the largest study in patients with ARDS in the UK.
The US ALTA study has recently been stopped due to futility and the results have been presented at the 2009 American Thoracic Society meeting and published in abstract form. 9 The study was terminated by the data monitoring board on the grounds of futility after 279 patients had been enrolled. The study found there were no significant differences in ventilator-free days to day 28, the primary study endpoint or in 60-day mortality between the two groups. After adjustment for baseline differences in shock and APACHE III score, there continued to be no significant difference in the main clinical outcomes. What are the implications of this study for the ongoing BALTI-2 study? There are a number of important differences between the ALTA and the BALTI-2 studies.
Nebulised drug administration in ALI/ARDS may be associated with sub-optimal delivery of the drug to the site of injury
The ALTA study used the nebulised route. However, the efficacy of nebulised salbutamol in ALI/ARDS had not previously been tested in a phase II trial. In patients with ALI/ARDS, inhaled drug therapy is associated with potential difficulties in delivery of the drug to the alveolar sites of injury. Indeed, the failure of drug delivery via the inhaled route is suggested to be one of the key factors implicated in the failure of other potentially useful drug therapies in ARDS in the past. 10, 11 In contrast the BALTI-2 study is investigating whether intravenous salbutamol, which is supported by the pilot data from the BALTI-1 study, 8 is effective.
Less severely ill patients with ALI may not benefit from salbutamol
Another important difference is the patient cohort studied. ALTA randomised patients with ALI who had an overall 60-day mortality of approximately 20%, while BALTI-2 is recruiting patients with ARDS. There may be important differences in the effectiveness according to severity of illness, particularly considering that in the BALTI-1 study, the benefit of intravenous salbutamol in the reduction of lung water was seen in a severely ill cohort with a 28-day mortality of approximately 60%. It may be that in a more severely ill cohort, alveolar fluid clearance (AFC) will be more significantly impaired and therefore more likely to benefit from an intervention which will upregulate AFC. In contrast in a A role for β β2 agonists in ARDS -the question remains unanswered DF McAuley, MA Matthay patient cohort that includes less severely ill ALI patients, AFC may be maintained and less likely to benefit from such a treatment. This hypothesis is supported by data which showed that in patients with maintained maximal AFC, mortality was similar to the ALTA study while in the patients with impaired AFC, mortality was much higher and similar to the mortality in BALTI-1. 12
Need for BALTI-2 to determine if intravenous salbutamol can improve outcomes in ARDS
It is therefore imperative that the negative study using nebulised salbutamol in ALI does not adversely influence recruitment to BALTI-2. Rather, the findings of the ALTA study add renewed support for the urgent need to investigate intravenous salbutamol in ARDS. It will be the responsibility and a major opportunity for the UK critical care community to ensure this trial recruits the required sample size to definitively answer the question whether beta agonists are beneficial in ARDS.
